Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precancerous Conditions 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Unspecified Adult Solid Tumor, Protocol Specific 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Papillomavirus Infections 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Infections 1Immunoblastic Lymphadenopathy 1Head and Neck Neoplasms 1Congenital Abnormalities 1Central Nervous System Neoplasms 1Carcinoma, Basal Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 20fludarabine phosphate 19Peripheral Blood Stem Cell Transplantation 18Whole-Body Irradiation 15Cyclosporine 12Mycophenolic Acid 11Etoposide 9Busulfan 9Prednisone 8Vincristine 7Tacrolimus 7Filgrastim 7Carboplatin 7Bortezomib 7Antilymphocyte Serum 7Methotrexate 6Everolimus 6Doxorubicin 6Vorinostat 5Rituximab 5Gemcitabine 5Therapeutics 4Radiotherapy 4Panobinostat 4Paclitaxel 4Melphalan 4Lenalidomide 4Gene Expression Profiling 4Methylprednisolone 3MLN 8237 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Immunoblastic Lymphadenopathy × Comparative Genomic Hybridization × Clear all
NCT01336933 2023-09-22

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

University of Nebraska

Phase 2 Completed
34 enrolled 12 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡